TSS
NVLN

Two Sigma Securities’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Two Sigma Securities’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,630
Closed -$9K – 2664
2018
Q4 		$9K Buy
+10,630
New +$12K ﹤0.01% 2029

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Securities's NVLN Position: Q1 2019 in Review

Two Sigma Securities sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q1 2019, closing a stake of 10,630 shares — an estimated $9K sold.

Two Sigma Securities first reported a position in NVLN in Q4 2018 and held it in 1 quarter. The position peaked at $9K in Q4 2018. 35 funds tracked by Wall St. Rank hold NVLN as of Q1 2019.

  • Two Sigma Securities reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q1 2019 after selling out during the quarter.
  • Two Sigma Securities sold 10,630 Novelion Therapeutics Inc. Common Shares shares in Q1 2019, an estimated $9K.
  • Two Sigma Securities first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2018 and held it in 1 quarter.
  • Two Sigma Securities's Novelion Therapeutics Inc. Common Shares position peaked at $9K in Q4 2018.
  • 35 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q1 2019.

Based on Two Sigma Securities's 13F filing for Q1 2019, filed 15 May 2019.